Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.
Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) is a clinical stage biotechnology company developing immune-modulating therapies centered on the CD40 Ligand (CD40L) pathway. The company’s news flow largely reflects progress with its lead investigational product, tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand that Eledon describes as having broad therapeutic potential.
News updates for ELDN commonly cover clinical trial milestones in kidney allograft transplantation, islet cell transplantation, xenotransplantation and amyotrophic lateral sclerosis (ALS). For example, Eledon has issued press releases on Phase 2 BESTOW trial results in de novo kidney transplant recipients, highlighting kidney function outcomes, safety and tolerability compared with tacrolimus-based regimens. Additional announcements have detailed updated data from a Phase 1b open-label kidney transplant study and long-term extension work.
Another recurring theme in Eledon’s news is the use of tegoprubart in islet transplantation for individuals with type 1 diabetes. The company has reported preliminary results from an investigator-initiated trial at the University of Chicago Medicine’s Transplant Institute, describing insulin independence and improved glycemic control in the first treated subjects. Eledon also issues updates on tegoprubart’s role in xenotransplantation, including its use as a key component of immunosuppression regimens in pig-to-human kidney transplant procedures at Massachusetts General Hospital.
Investors following ELDN news can also expect announcements related to scientific conference presentations, participation in healthcare conferences, financing transactions such as underwritten public offerings of common stock and pre-funded warrants, and selected financial results. This news page aggregates such disclosures so readers can review Eledon’s reported clinical data, corporate developments and regulatory-related communications over time.
Eledon Pharmaceuticals (Nasdaq: ELDN) reported 2025 operational and financial results on March 19, 2026, highlighting clinical progress for tegoprubart.
Key points: FDA Orphan Drug designation for liver transplantation, 24-month kidney transplant eGFR rose from 67.0 to 74.2 mL/min/1.73 m², islet transplant results showed 10/10 patients >4 weeks insulin independent (mean HbA1c ~5.35%), R&D $66.3M, net loss $45.6M ($0.52/share); adjusted net loss $79.1M.
Eledon (NASDAQ: ELDN) reported updated investigator-initiated islet transplant data presented March 2026 from a 12-patient UChicago Medicine cohort treated with tegoprubart. All 10 patients >4 weeks post-transplant achieved insulin independence and mean HbA1c ~5.35%. No rejection, no de novo donor-specific HLA antibodies, and no nephrotoxicity, hypertension or neurotoxicity were observed. Tegoprubart was generally well tolerated and immunosuppression-related adverse events were managed by lowering mycophenolic acid dose.
Findings support CD40L blockade as a calcineurin inhibitor-free option for islet graft protection and inform planned regulatory engagement later in 2026.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced that the FDA granted Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation on March 10, 2026. Tegoprubart previously held orphan designations for pancreatic islet transplantation and ALS.
The company cites kidney transplant clinical studies and preclinical liver data supporting further evaluation, and anticipates an investigator-sponsored clinical trial to begin later in 2026.
NewcelX (Nasdaq: NCEL) announced a collaborative research agreement with Eledon Pharmaceuticals (Nasdaq: ELDN) to evaluate combination strategies pairing NewcelX's lead stem-cell-derived islet program, NCEL-101, with Eledon's anti-CD40L antibody tegoprubart (AT-1501).
The collaboration leverages clinical experience from >100 transplant patients treated with tegoprubart and aims to support durable, immune-protected islet replacement, potentially clarifying regulatory pathways and accelerating NCEL-101 development toward pivotal milestones.
Eledon Pharmaceuticals (Nasdaq: ELDN) will participate in the Leerink Partners 2026 Global Healthcare Conference.
Chief Executive Officer David-Alexandre C. Gros, M.D. and President & Chief Scientific Officer Steven Perrin, Ph.D. will appear in a fireside chat on March 11, 2026 at 1:40 p.m. ET. A live webcast requires advance registration and a replay will be posted under Events on the company website.
Eledon (Nasdaq: ELDN) announced that Steven Perrin, Ph.D., President and Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 10:00 a.m. ET (7:00 a.m. PT).
According to the company, the session will be webcast live with a replay available afterward on Eledon’s website under Events.
Eledon Pharmaceuticals (Nasdaq: ELDN) will present 24-month follow-up data from eight patients in a Phase 1b long-term extension evaluating tegoprubart in de novo kidney transplant recipients at the American Society of Transplant Surgeons Winter Symposium, January 23–25, 2026.
Key results from the eight-patient cohort: no biopsy-proven acute rejection, no graft loss, no deaths, no new-onset diabetes mellitus, and no de novo donor-specific antibody formation during the study period. Mean eGFR rose from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months. Poster #62 will be presented January 23, 2026; the poster will be posted in the company's Investors section after the presentation.
Eledon Pharmaceuticals (Nasdaq: ELDN) summarized 2025 progress and provided a 2026 outlook centered on tegoprubart development across kidney allotransplantation, islet transplantation and xenotransplantation. Key 2025 results: Phase 2 BESTOW showed a mean eGFR of 69 mL/min/1.73 m² (n=51) at 12 months and demonstrated non-inferiority versus tacrolimus on an efficacy-failure composite (22.2% vs. 17.2% using a 20% non-inferiority margin). Investigator-led islet transplants (UChicago) reported insulin independence in the first six patients. Tegoprubart was used in four pig-to-human xenotransplants (three at MGH). The company completed a $57.5 million financing, expected to fund operations into 2Q 2027. Anticipated 2026 milestones include FDA guidance on Phase 3 design and multiple long-term data readouts.
Eledon Pharmaceuticals (Nasdaq: ELDN) announced that CEO David-Alexandre C. Gros, M.D. will participate in a fireside chat at the 37th Annual Piper Sandler Healthcare Conference on Thursday, December 4, 2025 at 8:50 a.m. ET (5:50 a.m. PT).
The session will be available via live webcast with a replay accessible on the company website under Events for registered attendees.
Eledon (NASDAQ: ELDN) reported preliminary results from the first six type 1 diabetes patients in an investigator-initiated islet transplant trial using tegoprubart as the core tacrolimus-free immunosuppressant.
All six subjects achieved and maintained insulin independence after one or two transplants; three patients have been insulin-free >15 months, one reached HbA1c 4.7% for >15 months, two patients reached insulin independence ≈4 weeks post-transplant with HbA1c <6% for >3 months, and a sixth is insulin-free with HbA1c 5.3%. No serious infections, thromboembolic events, rejection events, or kidney/neurologic toxicities were reported.